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Abstract
Background: Although expression of MTA1 inversely correlates with the nuclear localization of ERα, the effect and
molecular mechanism of ERα regulation of MTA1 remain unknown.
Methods: Quantitative real-time PCR and western blot analyses were used to measure levels of MTA1. The effect
on HCC cell proliferation and invasion was assessed by EdU incorporation assays and Transwell, respectively. ShRNA
and dual-luciferase assays were used to investigate the regulatory relationship between MTA1 and ERα in cell lines.
Results: We found that MTA1 gene regulation by ERα may be influenced by nuclear corepressors. The MTA1
promoter has three functional ER-element half-sites that lead to decreased MTA1 transcription and expression.
ERα overexpression suppressed the proliferation and invasion of hepatocellular carcinoma cells (HCC). In
addition, overexpression of MTA1 attenuated ERα-mediated suppression of the proliferation and invasion of
HCC cells and tumor formation in vivo. These results suggested feedback regulation between ERα and MTA1. In
summary, our results demonstrated that ERα suppressed proliferation and invasion of human HCC cells through
downregulation of MTA1 transcription.
Conclusions: Our study is an improved description of the mechanisms of the suppressive effect of ERα on
HCCs, adding understanding to the gender disparity of HCC progression.
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Introduction
Many studies have explored the expression levels of
MTA family members, especially MTA1, in human
cancers [1]. MTA1 gene expression correlates with
cancer progression and degree of invasion for hepato-
cellular carcinoma (HCC) and other carcinomas
[2–5]. Of 20 HCC specimens with vascular invasion,
19 (95 %) displayed strong MTA1 expression. Overex-
pression of MTA1 also significantly correlates with
large tumor size [6]. Increased MTA1 expression in
HCC correlates with larger tumors, perinodal exten-
sion, and microvascular invasion [7]. High expression
of the MTA1 gene is suggested to be a prognostic in-
dicator after curative hepatectomy for HCC [2, 3].
Other data indicate that MTA1 is closely associated
with microvascular invasion, frequent postoperative
recurrence, and poor survival of HCC patients, espe-
cially those with HBV-associated HCC [7]. MTA1 is
overexpressed in patients with invasive HBV-
associated HCC. MTA1 overexpression is associated
with shorter survival of patients with HBV-associated
HCC after curative resection [8]. Previous reports also
indicate that large tumors are more common in estro-
gen receptor (ER)-negative HCC. Furthermore, in a
normal hepatocyte cell line, MTA1 expression was
absent or minimal, whereas ERα was present in the
nucleus [9]. Expression of MTA1 inversely correlates
with ERα nuclear localization [6].
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Several lines of evidence suggest involvement of sex
hormones and their receptors in liver carcinogenesis.
ERα is expressed in the liver of healthy individuals and
patients with chronic hepatitis and HCC [10]. ER-positive
HCC is malignant and has a better prognosis than ER-
negative HCC [9]. HCC occurs more often in men than
women by a ratio that ranges from 2:1 to 11:1 in several
cohort reports [11]. Estrogen, which exerts its biological
function through ERs, inhibits HBV replication [12]. A
previous study showed that, in women, the risk of HCC
is inversely related to age of menopause and number of
full-term pregnancies [13]. This finding is consistent
with animal studies showing that ovariectomy increases
susceptibility to HCC in female mice [14]. ER is signifi-
cantly downregulated in HCCs, both by immunohisto-
chemistry staining and receptor-binding assays [15–18].
The steroid hormone 17 β-estradiol (E2) is important for
controlling the expression of genes involved in a variety of
biological processes including reproduction, development,
and HCC progression. ERα is the major ER in the
mammary epithelium. Ligand-activated ERα translocates
to the nucleus, binds to estrogen response elements
(EREs) in target gene promoters, and stimulates or re-
presses gene transcription [19, 20]. The consensus ERE is
a 13-bp palindromic sequence containing two inverted re-
peats of 5′-GGATC-3′ separated by three base pairs. ERα
binds to nonperfect or half ERE sequences, particularly
in the context of appropriate flanking sequences [21].
Corepressors are crucial regulators of ERα-mediated
action and they might inhibit HCC development. An
increasing number of ERα corepressors are being reported
[22]. A previous study found that overexpression of ERα
decreases PPARγ expression at the transcriptional and
translational level in a ligand-dependent manner [23].
Among ER corepressors, NCoR and SMRT are widely
characterized molecules implicated in transcriptional
silencing in the absence of ligands [24]. Given the im-
portance of ERα in HCC, the role of ERα corepressors
in the molecular mechanism of ERα activity needs to
be better understood.
In this study, we investigated the effects of ERα on three
half-ERE sequences of the MTA1 promoter in HCC. Prolif-
eration and invasion assays and animal model experiments
provided evidence that inhibition of MTA1 by ERα is im-
portant for attenuating HCC progression. These findings
are an improved characterization of the molecular events
underlying the gender inconsistency of HCC progression.
Materials and methods
Ethics statement
All animal work was conducted under the institutional
guidelines of Jiangsu Province and approved by the Use
Committee for Animal Care.
Chromatin immunoprecipitation
ChIP assays were performed by Pierce™ Agarose ChIP
Kit (Thermo Fisher Scientific, Rockford, USA). HepG2
cells were treated with formaldehyde and incubated for
10 min to generate DNA-protein cross-links. Cell lysates
were then sonicated to generate chromatin fragments
and immunoprecipitated with ERα antibody or IgG as
control. Precipitated chromatin DNA was recovered
and analyzed by PCR. The PCR primers were: sense,
5′-CGCACGACCACCTGTCCA-3′, and anti-sense, 5′-G
CCCTTCCACCAGAACCC-3′. The acquired DNA was
resolved on a 2 % agarose gel and stained with Goldview.
Real-time PCR
RNAs were extracted from cells using TRIzol (Invitrogen,
California, USA) kit according to the manufacturer’s
instructions. Subsequently, total RNA was reverse tran-
scribed using SuperScript III reverse transcriptase (Invitro-
gen, California, USA). Real-time PCR was then performed
in ABI PRISM7500 system (Applied Biosystems, California,
USA), according to the manufacturer’s instructions. The
expression level of each gene was normalized by GAPDH
and reported as relative levels. The primers sequences for
real-time PCR were obtain from the PrimerBank online.
The PCR primers were: MTA1, sense, 5′-ACGCAACCCT
GTCAGTCTG-3′, and anti-sense, 5′-GGGCAGGTCCAC
CATTTCC-3′; GAPDH, sense, 5′-GGAGCGAGATCCCT
CCAAAAT-3′, and anti-sense, 5′- GGCTGTTGTCATAC
TTCTCATGG-3′.
(http://pga.mgh.harvard.edu/primerbank/).
Dual luciferase reporter assay
The MTA1 gene −600 ~ −1 region was cloned into the
pEZX-PG04 with Gaussia Luciferase (GLuc) and Se-
creted Alkaline Phosphatase (SEAP) labeled, named
pEZX-PG04-MTA1 (GeneCopoeia, Guangzhou, China).
For transient transfection, the plasmids were transfected
into cells directly by lipofectamine 2000 (Invitrogen,
USA). Secrete-Pair™ Dual Luminescence Assay kit (Gene-
Copoeia, Guangzhou, China) was performed 48 h after
transfection according to the manufacturer’s protocol and
detected with a Fluoroskan microplate reader (Thermo
Labsystems, Helsinki, Finland). The activities of Gaussia
Luciferase (GLuc) and Secreted Alkaline Phosphatase
(SEAP) from cell culture medium were analyzed using a
Secrete-Pair™ Dual Luminescence Assay kit according to
the manufacturer’s instructions. Calculate the ratio of lu-
minescence intensities (RLU, Relative Light Unit) of the
GLuc over SEAP. Compare the normalized GLuc activity
(GLuc/SEAP ratio) of all samples.
Lentivirus production and infection
pLV-GFP vector system were constructed for overex-
pression of ERα and MTA1; pLL3.7-GFP vector system
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were constructed for ERα shRNA. The shRNA sequences
were: 5′-AACGGCATGGAGCATCTCTACATTCAAGAG
ATGTAGAGATGCTCCATGCCTTTTTTC-3′ [25] and 5′-
AACTGGTTTACATGTCGACTAATTCAAGAGATTAG
TCGACATGTAAACCTTTTTTTC-3′ for ERα and scram-
ble, respectively. All constructs were sequence-verified. De-
tails are available on request. Lentivirus of ERα, MTA1, and
ERα shRNA were derived from our previous protocols [26].
The HCC cell lines HepG2 and Hep3B were obtained from
Chinese Academy of Sciences and maintained in DMEM
medium (Life Technologies, Carlsbad, CA, USA) supple-
mented with 10 % fetal bovine serum, 100 units/ml penicil-
lin, and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA,
USA) in a humidified 5 % CO2 incubator at 37 °C. The
Hep3B-ERα, HepG2-shERα, and Hep3B-ERα/MTA1 cells
were generated from our previous protocols [26].
Western blotting
Whole cells were washed in PBS and lysed in RIPA
lysis buffer supplemented with protease inhibitor cocktail
(Roche, Mannheim, Germany). Total protein was quanti-
fied using a BCA Protein Assay Kit (Beyotime, Jiangsu,
China), and an equal amount of whole cell lysates was re-
solved by SDS-polyacrylamide gel electrophoresis (PAGE)
and transferred to a polyvinylidene difluoride (PVDF)
membrane (Millipore, Eschborn, Germany). The blots
were blocked in BSA (5 % w/v in PBS + 0.1 % Tween
20) for 1 h at room temperature. The following primary
antibodies were used according to the manufacturer’s
instructions. Antibodies against ERα, MTA1, and β-actin
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). The appropriate secondary antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) were used at
1:1000–1:2000 (v/v) dilutions in PBS + 0.1 % Tween 20 for
1 h at room temperature, and the signals were revealed
using ECL kit(Thermo Scientific Pierce, Thermo Fisher
Scientific, Rockford, USA). The cells were induced with
10nM and 100 nM 17β-estradiol (E2) for 24 h.
CCK-8 assay
Cell proliferation was measured by using the Cell Counting
Kit-8 assay (CCK-8, Dojindo, Japan). Briefly, cells were
plated into 96-well plates at a density of 104 cells/well with
100 μL of culture medium. After adhesion the cells were in-
cubated for 24, 48 and 72 h. At the end of each culture
period, 10 μL CCK-8 reagent was added to each well and
incubated for another 4 h, then the absorbance was mea-
sured at 450 nm wavelength.
EdU assay
Cells (2 × 103 cells/well) were seeded in triplicate in 96-
well plates and incubated overnight. Cells were starved
in DMEM without FBS for 24 h and then incubated in
DMEM containing 5 % FBS. Then the EdU (5′-ethynyl-
2′-deoxyuridine) incorporation assay was performed to
quantify cell proliferation using the Cell-Light™ EdU
DNA Cell Proliferation Kit (Guangzhou Ribobio Co.,
Ltd, Guangzhou, China) according to the manufacturer’s
instructions. More than five random fields per well were
captured, and IPP 6.0 was used to calculate the percentage
of EdU-positive cells in total cells.
Transwell invasion assay
Cell invasion assays were evaluated using Transwell cell
migration plates (Corning, NY, USA) and 8-μm pore size
Matrigel invasion chambers (BD Biosciences, San Jose,
USA) according to the manufacturer’s instructions [23–27].
Cells (1.0 × 104) were seeded in serum-free medium into
the upper chamber and allowed to invade towards 10 %
FBS in the lower chamber. After 24 h incubation in 37 °C
and 5 % CO2, the cells invaded through the membrane and
adhered to the underside of the membrane. Then cells were
fixed and stained with crystal violet. The images were
acquired by using NIS Elements image analysis software
(Nikon, Tokyo, Japan). For the membrane images, we
measure the migrated cells using image analysis software
ImagePro Plus 6.0 (Media Cybernetics, Bethesda, USA).
Mice model
Nude mice were purchased from the Vital River Laborator-
ies (Beijing, China). All animals were used in accordance
with institutional guidelines and the current experiments
were approved by the Use Committee for Animal Care. All
cultures used for injection were sub-confluent and were
fed the day prior to use. The harvested cell suspension
was washed twice by centrifugation in medium containing
serum at room temperature and then resuspended in
medium without serum at 4 °C immediately prior to injec-
tion. The number of cells (1 × 105 cells) to be injected was
suspended in 0.1 ml PBS. The cells were were injected
subcutaneously (into groin). The animals were sacrificed
4 weeks after injection. Pictures were recorded with a
Nikon d800 digital camera (Nikon, Tokyo, Japan).
Statistical analysis
All results were expressed as the mean ± s.d. The Student’s
t-tests were used to analyse significant differences between
samples. All the histogram was evaluated by performing
GraphPad Prism, version 4.0 (GraphPad Software, San
Diego California, USA). Statistical analyses were per-
formed using Stata. 11.0. P <0.05 indicated statistically
significant.
Results
ERα binds the MTA1 promoter and downregulates MTA1
expression
Previous studies show that expression of MTA1 inversely
correlates with ERα nuclear localization [6]. We searched
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for EREs within the BMI1 promoter. We found three half-
ERE sites from −268 to −203 (Fig. 1a). To explore whether
ERα assembled a complex on the MTA1 promoter, we
performed chromatin immunoprecipitation (ChIP) assays.
ERα bound to the region between −512 to −178 that con-
tained the three half-ERE sites (Fig. 2b). To study the
regulation of the MTA1 promoter via the ERE half-sites,
we generated a wildtype MTA1 promoter fragment and a
mutant MTA1 promoter with a deletion from −600 to −1
including the three ERE half-sites. The MTA1 promoter
fragments were cloned into a pEZX-PG04 luciferase
reporter system. The luciferase activity of wildtype and
mutant type MTA1 promoter-luciferase vectors was tested
in Hep3B and HepG2 cells. Ectopic overexpression of ERα
significantly decreased MTA1 promoter activity in Hep3B
cells transfected with the wildtype MTA1 promoter vector
but had no effect on cells transfected with the mutant
MTA1 promoter vector (Fig. 1c). Transfection with ERα
shRNA increased MTA1 promoter activity in HepG2 cells
but did not have an effect on the mutant MTA1 promoter
(Fig. 1d). Together, these findings indicated that recruit-
ment of ERα to MTA1 promoter chromatin was accom-
panied by repressed MTA1 promoter activity.
ERα downregulated MTA1 expression in HCC cells
Hep3B cells were cultured in estrogen-free medium and
treated with various concentrations of E2 for 72 h. With
E2, MTA1 protein and mRNA decreased (Fig. 2a). Infecting
Hep3B cells with an ERα lentivirus at different MOIs re-
sulted in reduction of MTA1 protein and mRNA with in-
creasing lentivirus MOI (Fig. 2b). To further investigate the
regulatory effect of ERα, we knocked down ERα in HepG2
cells using shRNA lentivirus infection and observed MTA1
expression. As shown in Fig. 2c, knockdown of endogenous
ERα significantly increased MTA1 protein and mRNA in a
dose-dependent manner.
ERα suppressed the proliferation and invasion of HCC
cells
Based on these results, we hypothesized that the prolifera-
tion and invasion effects of MTA1 would be suppressed
by ERα in HCC cells. To determine if ERα overexpression
suppressed proliferation and invasion, we constructed the
cell line Hep3B-ERα, which overexpressed ERα. CCK-8
proliferation assays revealed that proliferation of Hep3B-
ERα cells was significantly reduced compared to control
Hep3B-vector cells (Fig. 3a). To verify this result, we used
5-ethynyl-2′-deoxyuridine (EdU) in dynamic proliferation
assays. Overexpression of ERα impaired the proliferation
of Hep3B cells (Fig. 3b). Because MTA1 enhances the
invasion of HCC, we used transwell invasion assays to
examine the effect of ERα on invasion. The invasive cap-
acity of Hep3B-ERα cells was significantly lower than con-
trol cells (Fig. 3c). Specific shRNA targeting ERα knocked
down endogenous ERα in HepG2 cells. ERα knockdown
increased the proliferation of HepG2-shERα cells compared
to control scramble-shRNA-treated cells (Fig. 3d). EdU
assays indicated that ERα knockdown increased cell prolif-
eration of HepG2-shERα cells (Fig. 3e). Matrigel invasion
assays also demonstrated that ablation of endogenous ERα
increased invasion by HepG2-shERα cells (Fig. 3f). Collect-
ively, these results provided evidence that ERα expression
was important for the aggressive phenotype of HCC cells.
Fig. 1 ERα bound to the MTA1 promoter and downregulated MTA1 expression. a Schematic representation of the MTA1 promoter region with
three half-ERE sites. Specific primers amplified –512 to −178 by PCR. b Chromatin immunoprecipitation (ChIP) assays used normal IgG or anti-ERα
to identify ERα binding sites on the MTA1 promoter in HepG2 cells. PCR product was 335 base pairs. Three half-ERE sites were deleted from the
wildtype MTA1 promoter for the mutant MTA1 promoter. Hep3B (c) and HepG2 (d) cells were cotransfected with luciferase vectors with wildtype
or mutant MTA1 promoter or control vector. Results were from three independent experiments and presented as mean ± SEM. *P < 0.05 by t-test
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Reestablishment of elevated MTA1 by ectopic expression
abrogated ERα-mediated suppression of proliferation and
invasion
MTA1 protein decreased in Hep3B-ERα cell lines in which
ERα was ectopically overexpressed. To determine if ERα
suppressed proliferation and invasion by reducing MTA1
expression, we constructed the cell line Hep3B-ERα/
MTA1, which expressed ERα and ectopically overexpressed
MTA1. Western blots showed that overexpression of
MTA1 decreased expression of ERα in some Hep3B-
ERα/MTA1 cells compared to Hep3B-ERα cells (Fig. 4a)
with feedback regulation between ERα and MTA1.
CCK-8 and EdU assays demonstrated that MTA1 over-
expression increased proliferation of Hep3B-ERα cells
(Fig. 4b and c). Matrigel invasion assays showed that
invasion of Hep3B-ERα cells significantly increased
(Fig. 4d).
To test whether ERα overexpression decreased tumor
formation by Hep3B cells, a subcutaneous injection model
was established in BALB/c nude mice. At 4 weeks after in-
jection of tumor cells, mice injected with Hep3B-ERα cells
showed decreased tumor sizes compare to mice injected
with Hep3B cells (Fig. 4e). Restoration of MTA1 expres-
sion resulted in significantly increased tumor sizes in
Hep3B-ERα/MTA1 (Fig. 4e). These findings suggested
that inhibition of MTA1 function by ERα impaired HCC
proliferation and invasion.
Discussion
Previous studies on gender disparities in HCC highlight
the linkage between oestrogen and inflammation-induced
carcinogenesis [28]. Physiological doses of estrogen sup-
press HCC metastasis by decreasing interleukin-6 and
hepatocyte growth factor expression in the tumor micro-
environment [29]. MiR-18a prevents translation of ER,
potentially blocking the protective effects of estrogen and
promoting the development of HCC in women [11]. Ele-
vated p53 promotes miR-18a processing to decrease ERα
in HCC in women [30]. Oestrogen modulates HCC malig-
nancy in vivo by reducing tumor cell invasion, arresting
cell cycle progression, and promoting apoptosis, character-
ized by decreased expression of MMP-2, MMP-9, PCNA,
cyclin A, cyclin D1, and Bcl-2, and increased expression of
cleaved caspase 3. ERα-mediated inhibition of NF-kappaB
Fig. 2 ERα decreased MTA1 expression in HCC cells. a Hep3B cells were maintained in phenol red-free DMEM with 10 % dextran-coated
charcoal-treated FBS for 48 h and cells treated with either ethanol vehicle or E2 (10 or 100 nM) for 72 h. Cells were harvested and analyzed for
MTA1 mRNA (right) and protein. Results were from three independent experiments and presented as mean ± SEM. b Western blot and real-time
PCR analysis (right) for MTA1 protein and mRNA in Hep3B cells with MOI 20 or 60 ERα lentivirus infection. Results were from three independent
experiments and presented as mean ± SEM. c Western blot and real-time PCR analysis (right) for MTA1 protein and mRNA in HepG2 cells with
MOI 20 or 60 for shRNA-ERα lentivirus infection (n = 3, mean ± SEM) *P < 0.05, **P < 0.01 by t-test
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binding is a pivotal event [23, 31]. Consistent with recent
reports, we found that overexpression of ERα suppressed
HCC proliferation and invasion and decreased MTA1
expression. In our previous study, we found that PTPRO
expression results in pathological deficiency and gender
bias in HCC, which could be attributed to ERα regulation
[26]. Overexpression of miR-22 in male tumor adjacent
tissue was associated with downregulated ERα expression,
potentially by attenuating the protective effect of estrogen
and causing increased IL-1α expression [32] and STAT3
and IL-1α involved in inflammation and stemness inducible
of HCC progression. These mechanisms might be respon-
sible of the in vivo effect of ERa on reduction of tumor
growth in this study which could not be fully appreciated in
the in vitro experiments on cell proliferation.
Transcriptional activation by ERα is a complex and
multistep process that is influenced by coactivator and
corepressor proteins that either positively or nega-
tively modulate ERα-mediated transcriptional activity
[21, 33]. The transcriptional activity of ERα is modified by
coactivators, corepressors, and chromatin remodeling
complexes. In our study, ERα was recruited to the MTA1
promoter chromatin to repress MTA1 promoter activity
and downregulate MTA1 expression. Different ERα core-
pressors regulate steroid receptor activity through a variety
of mechanisms, including formation of multiprotein
Fig. 3 ERα suppressed proliferation and invasion of HCC cells. a CCK-8 assays showed that overexpression of ERα inhibited Hep3B cell growth.
Absorbance at 450 nm was measured. Results were from three independent experiments and presented as mean ± SEM. b Bright cyan, EdU positive.
EdU assays showed that ERα overexpression decreased the percent of EdU-positive in Hep3B cells compared to controls (n = 3, mean ± SEM).
c Overexpression of ERα reduced invasion by Hep3B cells in transwell assays (n = 3, mean ± SEM). d CCK-8 assays showed that knockdown of
ERα increased HepG2 cell growth (n = 3, mean ± SEM). e Bright cyan, EdU-positive. EdU assays showed that ERα knockdown increased the percent of
EdU-positive HepG2 cells compared to controls (n = 3, mean ± SEM). f Knockdown of ERα increased invasion by HepG2 cells in transwell assays
(n = 3, mean ± SEM) *P < 0.05 by t-test
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complexes that affect chromatin remodeling, histone deace-
tylation, or basal transcription [21]. Transcriptional repres-
sion, which is crucial for diverse biological processes, is
mediated in part by non-DNA-binding corepressors [19].
Transcriptional repression by tamoxifen-bound ER at E-
regulated gene promoters involves a dynamic interplay of
multiple distinct chromatin-modifying and remodeling
complexes [34]. Overexpression of ERα decreases PPARγ
expression at the transcriptional and translational level
in a ligand-dependent manner [35]. We hypothesized that
expression of MTA1 would be determined by the level of
ERα. Additionally, the ERα-SP1 complex binds to the prox-
imal and distal sites of the TNFα gene promoter and in-
duces expression of active caspase three in a ligand-
dependent manner [36]. ERα inhibits the epithelial-
mesenchymal transition by suppressing Bmi1 in breast
cancer [37]. The N-terminus of NCOR2 interacts with
other transcriptional corepressors to regulate transcription
and its C-terminus binds to ERα [38]. The transcriptional
corepressor TLE3 is recruited to chromatin by FoxA1 at
several ER-binding sites throughout the genome. TLE3
mediates repression via interaction with HDACs to
regulate histone acetylation [39]. Foxa factors have a
dominant effect on gender specificity in HCC develop-
ment, while Foxa-dependent ERα and AR have opposing
effects in HCC, with ERα-mediated estrogen signaling
protective against HCC [40]. One of these mechanisms
could be involved in regulation of MTA1.
MTA1 and MTA1s are corepressor proteins that act in
different ways to prevent ERα transcriptional activity [41].
The shRNA targeted against MTA1 could specifically me-
diate the MTA1 gene silence and consequentially recover
Fig. 4 Restoration of elevated MTA1 by ectopic expression abrogated ERα-mediated suppression of proliferation and invasion. a Western blots
showed that Hep3B-ERα/MTA1 cells exhibited ERα and MTA1 ectopic expression after ERα or MTA1 lentivirus infection. b MTA1 overexpression
increased growth of Hep3B-ERα/MTA1 compared to Hep3B-ERα cells. Absorbance at 450 nm was measured. Results were from three independent
experiments and presented as mean ± SEM. c Bright cyan, EdU-positive. EdU assays showed that restoration of MTA1 increased the percent of
EdU-positive cells compared to Hep3B-ERα cells (n = 3, mean ± SEM). d Representative images of transwell invasion assays. MTA1 overexpression
increased invasion by Hep3B-ERα/MTA1 cells compared to Hep3B-ERα cells (n = 3, mean ± SEM). e Macroscopic images (left) and weights of
subcutaneous tumors (right) on day 28 after s.c.-administered Hep3B-ERα/MTA1, Hep3B-ERα and control cells. Data are mean ± SEM of tumor
weights (n = 6 each). *P < 0.05 by t-test
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the protein expression of ERα [42]. MTA1-TFAP2C or the
MTA1-IFI16 complex may contribute to the epigenetic
regulation of ERα expression in breast cancer [43]. MTA1
and MICoA might transmodulate each other’s functions.
Any potential deregulation of MTA1 is likely to contribute
to the functional inactivation of the ER pathway, presum-
ably by derecruitment of MICoA from chromatin with ER
promoter targets [44]. The MTA3 promoter has a func-
tional ER element half-site and MTA3 gene regulation by
ER is influenced by dynamic changes in levels of nuclear
coregulators, including MTA1 [45]. Overexpression of
MTA1 resulted in a few Hep3B-ERα/MTA1 cells with de-
creased expression of ERα compared to Hep3B-ERα cell
(Fig. 4a). Based on these results, feedback regulation be-
tween ERα and MTA1 might occur. This will be studied
in our further research.
Conclusions
Our results showed that ERα suppressed proliferation and
invasion of human HCC cells through transcriptional
downregulation of MTA1. Our study is an improved
description of the mechanisms of the suppressive effects
of ERα on HCC and adds understanding to the gender
disparity in HCC progression.
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